Perrigo
This article was originally published in The Tan Sheet
Executive Summary
Allegan, Mich.-based generics firm saw "strong sales of loratadine D-24, the store brand equivalent to Claritin D-24; had strong initial shipments of loratadine syrup and loratadine quick-dissolve tablets; and experienced growth in the vitamin category" during the third quarter ended March 27, Perrigo CEO David Gibbons reports in an April 23 earnings call. Overall net sales grew 14% to $230.7 mil. compared to the year-ago quarter. Results were driven by "new products launched earlier in the year, new products shipping in the current period, and revenue from Peter Black Pharmaceuticals, a UK-based nutritional business acquired in December 2003"...